知镜 Cognispect · 医学文献与研究工作台

Antibiotic prophylaxis and empirical therapy for intra-abdominal infections: a systematic review and network meta-analysis.

Singh P, Sharma M, Gupta K, Dhiman V, Verma A, Singh Malhi A, Anand S.
Expert review of anti-infective therapy · 2026-10-14 · PMID 42844216

文献摘要

Introduction The optimal choice of antibiotic prophylaxis and empirical therapy for suspected acute intra-abdominal infections (IAIs) remains uncertain, especially in light of increasing antimicrobial resistance. This systematic review and network meta-analysis (NMA) compared the efficacy and safety of antibiotic classes for empirical treatment of suspected IAIs and for prophylaxis in at-risk populations. Methods PubMed, Embase, SCOPUS, Web of Science, and CENTRAL were searched until 24 January 2026 (PROSPERO-CRD420251106514). Eligible studies assessed empiric antibiotic therapy or prophylaxis for IAI. Outcomes included treatment success, intra-abdominal and wound infection rates, morbidity, mortality, and adverse events. Treatment and prophylaxis data were analyzed as separate networks per outcome using frequentist random-effects NMA, with certainty graded via GRADE. Results 19 studies (2,910 patients) on treatment and 9 studies (3,014 patients) on prophylaxis, across eight antibiotic classes, were included. In the treatment setting, carbapenems were associated with significantly higher treatment success than β-lactam/β-lactamase inhibitor [RR(95%CI)=1.06 (1.01-1.62)] and ranked highest by SUCRA for treatment success and adverse events. In the prophylaxis setting, cephalosporin was associated with a lower risk of wound infection than carbapenem [RR(95%CI)=0.79 (0.70-0.88)] and β-lactam/β-lactamase inhibitor [RR(95%CI)=0.38 (0.16-0.91)]. Sensitivity analyses confirmed robustness; certainty ranged from moderate to very low, mainly due to imprecision. Conclusion Carbapenems provide the highest efficacy for empirical IAI treatment but require judicious use given resistance concerns. This benefit does not extend to prophylaxis, where narrower-spectrum agents such as cephalosporins performed well. Further high-quality trials incorporating newer agents and resistance outcomes are needed.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。